Pfizer Corporation

Pharmacia Corporation

Jost Chemical Company

Euclises Pharmaceuticals, Inc.

Kevin D Jerome

Paul Vincent Rucker

Rajesh Devraj

Mark G Obukowicz

Lisa Maria Olson

Ronald Keith Webber

Xiao Hu

Terri L Boehm

Balekudru Devadas

Shuang Liu

Richard C Durley

Brian S Hickory

Ian L Scott

Michele A Promo

Shaun Raj Selness

Hengmiao Cheng

Li Huang Xing

Thomas Dale Owen

Win Naing

John Walker

Aruna Sambandam

Hengmiao (Henry) Cheng

Edgardo Alvira

Huey S Shieh

Gary A Decresenzo

Heather M Madsen

Radhika M Blevis-Bal

Laura D Marruto

Jeff Hitchcock

Kevin F McGee

John Jeffrey Talley

Eduardo J Martinez

Joseph R Hardimon

Kasey L Morris

A zinc ascorbate glycinate co-salt having a formula of MC8H11NO8 and a suggested structure of: Formula (I). Where M is Ca, Mg, or Zn. The divalent metal ascorbate glycinate co-salt is formed as a powder having a metal content of about 8% to about 21% on an anhydrous basis and containing between 0.0-20.0% water.

Divalent metal ascorbate glycinate co-salt

The present invention provides NO-releasing NONOate(nitrogen bound)sulfonamide-linked-coxib anti-cancer agents, having the structure of Formula (I): wherein R, X, L, R, R, R, and Z are as defined in the detailed description; pharmaceutical compositions comprising at least one compound of Formula (I); and methods useful for healing wounds, preventing and treating cancer, or treating actinic keratosis, cystic fibrosis or acne, using a compound of Formula (I).

No-releasing nonoate(nitrogen-bound)sulfonamide-linked-coxib anti-cancer agents

The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.

Tricyclic compounds, compositions, and methods

Tricyclic compounds, compositions and methods

Diaryl substituted pyridinones

Tricyclic compound, compositions, and methods

Disclosed are compounds Formula Iand pharmaceutically acceptable salts thereof, wherein R, R, R, R, and Rare defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.

Substituted pyridinones

Growing community of inventors

St. Charles, MO, United States of America

Kevin D Jerome